Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

CellRapeutics™ Cytokine Release Test Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Why Monitoring Cytokines In CAR-T Therapy

Cytokines are an important player in the context of CAR-T cell therapy for cancer. When CAR-T cells encounter cancer cells expressing the target antigen, CAR-T cells are activated and can secrete large amounts of cytokines as part of the immune response. However, excessive and uncontrolled cytokine release can lead to severe adverse reactions known as cytokine release syndrome (CRS). After the infusion of CAR-T cells, patients potentially experience CRS. Therefore, the cytokine release test is a necessary step to ensure the safety and efficacy of the final product and provides valuable insights into the immune response generated by the CAR-T treatment. Creative Biolabs provides various cytokine release test services, such as ELISA-based cytokine detection using highly sensitive antibodies to ensure accurate and reliable results.

Fig.1 CAR-T therapy and CRS.¹

Our Services

• Various Cytokine Release Assays
  At Creative Biolabs, we provide various assays to measure cytokine production during the development of CAR-T cell therapy products. Our techniques including ELISA, ELISPOT, and multiplex bead array are used for the quantitative measurement of cytokines in serum, plasma, tissue culture supernatants, and other biological fluids. These techniques have been extensively used in basic research and clinical trials to assess the levels of cytokines in CAR-T cell therapy.
  
  • ELISA allows for the quantitative measurement of cytokines in various biological samples.
  • ELISPOT allows for the detection of individual cytokine-producing cells.
  • Multiplex bead array allows for the simultaneous measurement of multiple cytokines in a single sample.

Please get in touch with us for more details.

• Detection of Various Cytokines

We offer multiple cytokines release assays to evaluate the release of various cytokines, including but not limited to:

Advantages

• High sensitivity: Our assays can detect cytokines at very low concentrations, allowing us to detect small changes in cytokine levels.
• Standardized protocols: We use standardized protocols for all our assays, ensuring consistent and reliable results.
• Expertise: Our team of experts has extensive experience in cytokine detection and CAR-T cell therapy product development, ensuring that we provide the best possible service to our clients.

Support Data

Here are some representative data for CAR-T cell cytokine release assays.

Case 1: Analysis of cytokine release by bead-based immunoassay.

Fig.2 Analysis of cytokine levels in plasma of CAR T cells.²

Case 2: Analysis of cytokine release by ELISA.

Fig.3 Analysis of cytokine release of anti-hGPC3 CAR-T cells in supernatants.³

References

1. Cosenza, Maria, Stefano Sacchi, and Samantha Pozzi. "Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment." International Journal of Molecular Sciences 22.14 (2021): 7652.
2. Lee, Yong Gu, et al. "Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters." Nature communications 10.1 (2019): 2681.
3. Liu, Xuan, et al. "Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release." Therapeutic advances in medical oncology 12 (2020): 1758835920910347.